Intrinsic value of Steris - STE

Previous Close

$111.96

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$111.96

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of STE stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 9.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  16.70
  15.53
  14.48
  13.53
  12.68
  11.91
  11.22
  10.60
  10.04
  9.53
  9.08
  8.67
  8.30
  7.97
  7.68
  7.41
  7.17
  6.95
  6.76
  6.58
  6.42
  6.28
  6.15
  6.04
  5.93
  5.84
  5.76
  5.68
  5.61
  5.55
Revenue, $m
  3,049
  3,523
  4,033
  4,579
  5,159
  5,773
  6,421
  7,101
  7,814
  8,559
  9,336
  10,146
  10,988
  11,864
  12,775
  13,722
  14,705
  15,728
  16,790
  17,895
  19,044
  20,240
  21,486
  22,783
  24,134
  25,544
  27,014
  28,549
  30,151
  31,824
Variable operating expenses, $m
  2,710
  3,085
  3,489
  3,921
  4,381
  4,867
  5,380
  5,919
  6,483
  7,073
  7,393
  8,034
  8,701
  9,395
  10,116
  10,866
  11,645
  12,454
  13,296
  14,171
  15,081
  16,028
  17,014
  18,041
  19,111
  20,227
  21,392
  22,607
  23,876
  25,201
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  2,710
  3,085
  3,489
  3,921
  4,381
  4,867
  5,380
  5,919
  6,483
  7,073
  7,393
  8,034
  8,701
  9,395
  10,116
  10,866
  11,645
  12,454
  13,296
  14,171
  15,081
  16,028
  17,014
  18,041
  19,111
  20,227
  21,392
  22,607
  23,876
  25,201
Operating income, $m
  339
  438
  544
  657
  778
  906
  1,041
  1,182
  1,331
  1,486
  1,943
  2,112
  2,287
  2,469
  2,659
  2,856
  3,061
  3,273
  3,494
  3,724
  3,964
  4,213
  4,472
  4,742
  5,023
  5,316
  5,622
  5,942
  6,275
  6,624
EBITDA, $m
  1,114
  1,287
  1,473
  1,673
  1,885
  2,109
  2,346
  2,594
  2,855
  3,127
  3,411
  3,706
  4,014
  4,334
  4,667
  5,013
  5,372
  5,746
  6,134
  6,538
  6,957
  7,394
  7,849
  8,323
  8,817
  9,332
  9,869
  10,430
  11,015
  11,626
Interest expense (income), $m
  43
  80
  99
  120
  142
  166
  192
  219
  247
  277
  308
  341
  375
  411
  448
  486
  526
  568
  611
  656
  703
  751
  802
  854
  909
  966
  1,025
  1,087
  1,152
  1,219
  1,290
Earnings before tax, $m
  259
  339
  424
  515
  612
  714
  822
  935
  1,054
  1,177
  1,602
  1,736
  1,876
  2,022
  2,173
  2,330
  2,493
  2,662
  2,838
  3,022
  3,212
  3,411
  3,617
  3,833
  4,057
  4,291
  4,535
  4,790
  5,056
  5,334
Tax expense, $m
  70
  91
  114
  139
  165
  193
  222
  253
  284
  318
  433
  469
  507
  546
  587
  629
  673
  719
  766
  816
  867
  921
  977
  1,035
  1,095
  1,159
  1,224
  1,293
  1,365
  1,440
Net income, $m
  189
  247
  309
  376
  447
  521
  600
  683
  769
  860
  1,169
  1,268
  1,370
  1,476
  1,586
  1,701
  1,820
  1,943
  2,072
  2,206
  2,345
  2,490
  2,641
  2,798
  2,962
  3,132
  3,311
  3,497
  3,691
  3,894

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  5,743
  6,635
  7,595
  8,623
  9,716
  10,873
  12,092
  13,374
  14,716
  16,119
  17,582
  19,107
  20,694
  22,344
  24,059
  25,841
  27,694
  29,619
  31,620
  33,701
  35,865
  38,117
  40,462
  42,905
  45,451
  48,105
  50,874
  53,764
  56,781
  59,933
Adjusted assets (=assets-cash), $m
  5,743
  6,635
  7,595
  8,623
  9,716
  10,873
  12,092
  13,374
  14,716
  16,119
  17,582
  19,107
  20,694
  22,344
  24,059
  25,841
  27,694
  29,619
  31,620
  33,701
  35,865
  38,117
  40,462
  42,905
  45,451
  48,105
  50,874
  53,764
  56,781
  59,933
Revenue / Adjusted assets
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
  0.531
Average production assets, $m
  4,794
  5,538
  6,340
  7,198
  8,110
  9,076
  10,094
  11,163
  12,284
  13,455
  14,676
  15,949
  17,274
  18,651
  20,083
  21,571
  23,117
  24,724
  26,394
  28,131
  29,938
  31,818
  33,775
  35,814
  37,939
  40,155
  42,466
  44,878
  47,397
  50,028
Working capital, $m
  76
  88
  101
  114
  129
  144
  161
  178
  195
  214
  233
  254
  275
  297
  319
  343
  368
  393
  420
  447
  476
  506
  537
  570
  603
  639
  675
  714
  754
  796
Total debt, $m
  1,834
  2,219
  2,634
  3,078
  3,550
  4,050
  4,577
  5,130
  5,710
  6,316
  6,948
  7,607
  8,293
  9,005
  9,746
  10,516
  11,317
  12,148
  13,013
  13,912
  14,847
  15,820
  16,833
  17,888
  18,988
  20,134
  21,330
  22,579
  23,882
  25,244
Total liabilities, $m
  2,481
  2,866
  3,281
  3,725
  4,197
  4,697
  5,224
  5,777
  6,357
  6,963
  7,595
  8,254
  8,940
  9,652
  10,393
  11,163
  11,964
  12,795
  13,660
  14,559
  15,494
  16,467
  17,480
  18,535
  19,635
  20,781
  21,978
  23,226
  24,529
  25,891
Total equity, $m
  3,262
  3,768
  4,314
  4,898
  5,518
  6,176
  6,868
  7,596
  8,359
  9,155
  9,987
  10,853
  11,754
  12,691
  13,665
  14,678
  15,730
  16,823
  17,960
  19,142
  20,371
  21,651
  22,983
  24,370
  25,816
  27,324
  28,896
  30,538
  32,252
  34,042
Total liabilities and equity, $m
  5,743
  6,634
  7,595
  8,623
  9,715
  10,873
  12,092
  13,373
  14,716
  16,118
  17,582
  19,107
  20,694
  22,343
  24,058
  25,841
  27,694
  29,618
  31,620
  33,701
  35,865
  38,118
  40,463
  42,905
  45,451
  48,105
  50,874
  53,764
  56,781
  59,933
Debt-to-equity ratio
  0.560
  0.590
  0.610
  0.630
  0.640
  0.660
  0.670
  0.680
  0.680
  0.690
  0.700
  0.700
  0.710
  0.710
  0.710
  0.720
  0.720
  0.720
  0.720
  0.730
  0.730
  0.730
  0.730
  0.730
  0.740
  0.740
  0.740
  0.740
  0.740
  0.740
Adjusted equity ratio
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  189
  247
  309
  376
  447
  521
  600
  683
  769
  860
  1,169
  1,268
  1,370
  1,476
  1,586
  1,701
  1,820
  1,943
  2,072
  2,206
  2,345
  2,490
  2,641
  2,798
  2,962
  3,132
  3,311
  3,497
  3,691
  3,894
Depreciation, amort., depletion, $m
  775
  849
  930
  1,015
  1,107
  1,203
  1,305
  1,412
  1,524
  1,641
  1,468
  1,595
  1,727
  1,865
  2,008
  2,157
  2,312
  2,472
  2,639
  2,813
  2,994
  3,182
  3,378
  3,581
  3,794
  4,015
  4,247
  4,488
  4,740
  5,003
Funds from operations, $m
  964
  1,097
  1,239
  1,391
  1,553
  1,725
  1,905
  2,095
  2,293
  2,501
  2,637
  2,862
  3,097
  3,341
  3,594
  3,858
  4,131
  4,416
  4,711
  5,019
  5,339
  5,672
  6,018
  6,379
  6,756
  7,148
  7,557
  7,984
  8,431
  8,897
Change in working capital, $m
  11
  12
  13
  14
  15
  15
  16
  17
  18
  19
  19
  20
  21
  22
  23
  24
  25
  26
  27
  28
  29
  30
  31
  32
  34
  35
  37
  38
  40
  42
Cash from operations, $m
  953
  1,085
  1,226
  1,378
  1,539
  1,709
  1,889
  2,078
  2,275
  2,482
  2,618
  2,842
  3,076
  3,319
  3,571
  3,834
  4,107
  4,390
  4,685
  4,991
  5,310
  5,642
  5,987
  6,347
  6,722
  7,113
  7,520
  7,946
  8,390
  8,855
Maintenance CAPEX, $m
  -411
  -479
  -554
  -634
  -720
  -811
  -908
  -1,009
  -1,116
  -1,228
  -1,345
  -1,468
  -1,595
  -1,727
  -1,865
  -2,008
  -2,157
  -2,312
  -2,472
  -2,639
  -2,813
  -2,994
  -3,182
  -3,378
  -3,581
  -3,794
  -4,015
  -4,247
  -4,488
  -4,740
New CAPEX, $m
  -685
  -744
  -802
  -858
  -912
  -966
  -1,018
  -1,070
  -1,120
  -1,171
  -1,222
  -1,273
  -1,324
  -1,377
  -1,432
  -1,488
  -1,546
  -1,607
  -1,670
  -1,737
  -1,807
  -1,880
  -1,957
  -2,039
  -2,125
  -2,216
  -2,311
  -2,412
  -2,519
  -2,631
Cash from investing activities, $m
  -1,096
  -1,223
  -1,356
  -1,492
  -1,632
  -1,777
  -1,926
  -2,079
  -2,236
  -2,399
  -2,567
  -2,741
  -2,919
  -3,104
  -3,297
  -3,496
  -3,703
  -3,919
  -4,142
  -4,376
  -4,620
  -4,874
  -5,139
  -5,417
  -5,706
  -6,010
  -6,326
  -6,659
  -7,007
  -7,371
Free cash flow, $m
  -143
  -139
  -129
  -114
  -93
  -68
  -37
  -1
  39
  83
  51
  102
  157
  214
  275
  338
  404
  472
  542
  615
  690
  768
  848
  930
  1,015
  1,103
  1,194
  1,287
  1,384
  1,484
Issuance/(repayment) of debt, $m
  355
  385
  415
  444
  472
  500
  527
  554
  580
  606
  632
  659
  685
  713
  741
  770
  800
  832
  864
  899
  935
  973
  1,013
  1,055
  1,100
  1,147
  1,196
  1,248
  1,304
  1,362
Issuance/(repurchase) of shares, $m
  274
  259
  236
  208
  174
  136
  93
  45
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  629
  644
  651
  652
  646
  636
  620
  599
  580
  606
  632
  659
  685
  713
  741
  770
  800
  832
  864
  899
  935
  973
  1,013
  1,055
  1,100
  1,147
  1,196
  1,248
  1,304
  1,362
Total cash flow (excl. dividends), $m
  486
  506
  522
  538
  553
  568
  583
  597
  618
  689
  683
  761
  842
  927
  1,016
  1,108
  1,204
  1,303
  1,407
  1,514
  1,625
  1,741
  1,861
  1,986
  2,115
  2,250
  2,390
  2,536
  2,687
  2,846
Retained Cash Flow (-), $m
  -463
  -507
  -546
  -584
  -621
  -657
  -693
  -728
  -762
  -797
  -831
  -866
  -901
  -937
  -974
  -1,012
  -1,052
  -1,093
  -1,137
  -1,182
  -1,229
  -1,279
  -1,332
  -1,387
  -1,446
  -1,508
  -1,573
  -1,641
  -1,714
  -1,790
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  18
  21
  25
  28
  32
  36
  40
  45
  50
  55
  60
  65
  71
  77
  83
  89
  96
  103
  110
  118
  125
  133
  142
  150
  159
  169
  179
  189
  200
  211
Cash available for distribution, $m
  23
  -1
  -24
  -46
  -68
  -89
  -110
  -130
  -144
  -108
  -148
  -105
  -59
  -10
  41
  95
  152
  210
  270
  332
  396
  462
  529
  598
  669
  742
  817
  894
  974
  1,055
Discount rate, %
  5.20
  5.46
  5.73
  6.02
  6.32
  6.64
  6.97
  7.32
  7.68
  8.07
  8.47
  8.89
  9.34
  9.81
  10.30
  10.81
  11.35
  11.92
  12.51
  13.14
  13.80
  14.49
  15.21
  15.97
  16.77
  17.61
  18.49
  19.41
  20.38
  21.40
PV of cash for distribution, $m
  22
  -1
  -20
  -36
  -50
  -61
  -69
  -74
  -74
  -50
  -61
  -38
  -19
  -3
  10
  18
  24
  28
  29
  28
  26
  24
  20
  17
  14
  11
  8
  6
  4
  3
Current shareholders' claim on cash, %
  97.2
  95.0
  93.3
  92.0
  91.0
  90.4
  90.0
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8
  89.8

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others. Its Corporate and other segment includes the Defense and Industrial business unit.

FINANCIAL RATIOS  of  Steris (STE)

Valuation Ratios
P/E Ratio 86.5
Price to Sales 3.6
Price to Book 3.4
Price to Tangible Book
Price to Cash Flow 22.4
Price to Free Cash Flow 37.9
Growth Rates
Sales Growth Rate 16.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 37.3%
Cap. Spend. - 3 Yr. Gr. Rate 15%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 52.8%
Total Debt to Equity 52.8%
Interest Coverage 5
Management Effectiveness
Return On Assets 2.6%
Ret/ On Assets - 3 Yr. Avg. 4.6%
Return On Total Capital 2.5%
Ret/ On T. Cap. - 3 Yr. Avg. 4.8%
Return On Equity 3.8%
Return On Equity - 3 Yr. Avg. 7.3%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 39.3%
Gross Margin - 3 Yr. Avg. 40.4%
EBITDA Margin 15.9%
EBITDA Margin - 3 Yr. Avg. 16.3%
Operating Margin 8.7%
Oper. Margin - 3 Yr. Avg. 10.2%
Pre-Tax Margin 7.1%
Pre-Tax Margin - 3 Yr. Avg. 8.7%
Net Profit Margin 4.2%
Net Profit Margin - 3 Yr. Avg. 5.5%
Effective Tax Rate 40%
Eff/ Tax Rate - 3 Yr. Avg. 36.8%
Payout Ratio 84.5%

STE stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the STE stock intrinsic value calculation we used $2613 million for the last fiscal year's total revenue generated by Steris. The default revenue input number comes from 2017 income statement of Steris. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our STE stock valuation model: a) initial revenue growth rate of 16.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.2%, whose default value for STE is calculated based on our internal credit rating of Steris, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Steris.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of STE stock the variable cost ratio is equal to 90.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for STE stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Steris.

Corporate tax rate of 27% is the nominal tax rate for Steris. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the STE stock is equal to 0.7%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for STE are equal to 157.2%.

Life of production assets of 10 years is the average useful life of capital assets used in Steris operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for STE is equal to 2.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2799 million for Steris - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 85 million for Steris is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Steris at the current share price and the inputted number of shares is $9.5 billion.

RELATED COMPANIES Price Int.Val. Rating
HRC Hill-Rom Holdi 94.60 50.70  sell
MMM 3M 201.95 175.63  hold
SYK Stryker 174.30 73.42  str.sell
JNJ Johnson&Johnso 125.85 126.96  hold
CNMD CONMED 73.43 27.17  str.sell
OMI Owens&Minor 17.45 28.37  str.buy

COMPANY NEWS

▶ Steris: Fiscal 4Q Earnings Snapshot   [May-09-18 06:35AM  Associated Press]
▶ Varex Imaging Names Rosebrough To Board Of Directors   [Apr-23-18 08:30AM  PR Newswire]
▶ CME, Estee Lauder, Roku & avoid this tech name   [Feb-20-18 02:42PM  CNBC Videos]
▶ STERIS plc to Host Earnings Call   [Feb-07-18 07:50AM  ACCESSWIRE]
▶ Steris beats 3Q profit forecasts   [06:29AM  Associated Press]
▶ Stocks Generating Improved Relative Strength: Steris   [Jan-16-18 03:00AM  Investor's Business Daily]
▶ Is It Too Late To Buy Steris Plc (NYSE:STE)?   [Jan-03-18 04:48PM  Simply Wall St.]
▶ STERIS Plc Value Analysis (NYSE:STE) : November 6, 2017   [Nov-06-17 01:19PM  Capital Cube]
▶ STERIS plc to Host Earnings Call   [Nov-01-17 08:00AM  ACCESSWIRE]
▶ Steris misses 2Q profit forecasts   [06:11AM  Associated Press]
▶ Should You Buy STERIS (STE) Ahead of Earnings?   [Oct-30-17 08:56AM  Zacks]
▶ ETFs with exposure to STERIS Plc : October 16, 2017   [Oct-16-17 09:59AM  Capital Cube]
▶ 5 MedTech Momentum Picks Investors Will Love   [Oct-13-17 09:27AM  Zacks]
▶ 5 MedTech Stocks for Stellar Returns in Q3   [Oct-10-17 04:59PM  Zacks]
▶ ETFs with exposure to STERIS Plc : October 3, 2017   [Oct-03-17 11:37AM  Capital Cube]
▶ When Should You Sell Steris Plc (STE)?   [Sep-29-17 03:02PM  Simply Wall St.]
▶ How Much Higher Can Medtech Climb As Investors Flee Pharma?   [Sep-14-17 05:36PM  Investor's Business Daily]
▶ Steris beats Street 1Q forecasts   [Aug-08-17 05:51PM  Associated Press]
▶ ETFs with exposure to STERIS Plc : August 4, 2017   [Aug-03-17 09:31PM  Capital Cube]
▶ ETFs with exposure to STERIS Plc : July 13, 2017   [Jul-13-17 04:37PM  Capital Cube]
▶ ETFs with exposure to STERIS Plc : June 20, 2017   [Jun-20-17 03:15PM  Capital Cube]
▶ UFP Technologies Elects Cynthia Feldmann to its Board   [Jun-09-17 11:29AM  GlobeNewswire]
▶ ETFs with exposure to STERIS Plc : June 5, 2017   [Jun-05-17 02:48PM  Capital Cube]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.